Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Atkins

Showing results (391-400 of 493) with videos related to

Pageof 50
Sort By:
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
JAMA Oncology|December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas Powles, Michael B Atkins, et al.
Pigment Cell & Melanoma Research|January 10, 2020
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directionsIsabella C Glitza, Keiran S M Smalley, Priscilla K Brastianos, et al.
The Lancet. Oncology|December 7, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThomas Powles, Elizabeth R Plimack, Denis Soulières, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinomaN Agarwal, J Brugarolas, P Ghatalia, et al.
Journal of Pain and Symptom Management|January 2, 2025
Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical TrialsSarah N Price, Ju-Whei Lee, Ilana F Gareen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) studyUday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Cancer|March 23, 2023
The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective studyShaked Lev-Ari, Michael Serzan, Tianmin Wu, et al.
Cancer|April 30, 2009
Innovations and challenges in renal cancer: summary statement from the Third Cambridge ConferenceMichael B Atkins, Ronald M Bukowski, Bernard J Escudier, et al.
Journal for Immunotherapy of Cancer|December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)Brian I Rini, Dena Battle, Robert A Figlin, et al.
Pageof 50

Showing results (391-400 of 493) with videos related to

Sort By:
Pageof 50
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
JAMA Oncology|December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas Powles, Michael B Atkins, et al.
Pigment Cell & Melanoma Research|January 10, 2020
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directionsIsabella C Glitza, Keiran S M Smalley, Priscilla K Brastianos, et al.
The Lancet. Oncology|December 7, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThomas Powles, Elizabeth R Plimack, Denis Soulières, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinomaN Agarwal, J Brugarolas, P Ghatalia, et al.
Journal of Pain and Symptom Management|January 2, 2025
Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical TrialsSarah N Price, Ju-Whei Lee, Ilana F Gareen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) studyUday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Cancer|March 23, 2023
The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective studyShaked Lev-Ari, Michael Serzan, Tianmin Wu, et al.
Cancer|April 30, 2009
Innovations and challenges in renal cancer: summary statement from the Third Cambridge ConferenceMichael B Atkins, Ronald M Bukowski, Bernard J Escudier, et al.
Journal for Immunotherapy of Cancer|December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)Brian I Rini, Dena Battle, Robert A Figlin, et al.
Pageof 50